US20080152800A1 - Process for the coating of biomedical articles - Google Patents

Process for the coating of biomedical articles Download PDF

Info

Publication number
US20080152800A1
US20080152800A1 US12/004,002 US400207A US2008152800A1 US 20080152800 A1 US20080152800 A1 US 20080152800A1 US 400207 A US400207 A US 400207A US 2008152800 A1 US2008152800 A1 US 2008152800A1
Authority
US
United States
Prior art keywords
solution
process according
biomedical article
treatment
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/004,002
Other versions
US8158192B2 (en
Inventor
Harald Bothe
Yasuo Matsuzawa
Bernhard Seiferling
Katharina Schmid
Heike Arndt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to NOVARTIS AG reassignment NOVARTIS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MATSUZAWA, YASUO, ANRDT, HEIKE, BOTHE, HARALD, SCHMID, KATHARINA, SEIFERLING, BERNHARD
Publication of US20080152800A1 publication Critical patent/US20080152800A1/en
Application granted granted Critical
Publication of US8158192B2 publication Critical patent/US8158192B2/en
Assigned to ALCON INC. reassignment ALCON INC. CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Assignors: NOVARTIS AG
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials

Definitions

  • the present invention relates to a process for the manufacture of coated articles such as biomedical articles, especially contact lenses, which are at least partly coated with a polyanionic polymer.
  • EP-A 1 153 964 and EP-A-1 287 060 both disclose polyanionic coatings on silicon hydrogel contact lenses, which are prepared by immersing the contact lenses in an aqueous solution of the polyanionic compound.
  • EP-A 1 252 222 discloses in Example 7 a silicon hydrogel lens coated with a polyacrylic acid and a polyallylamine in a molar ratio of 10:1; the coating is obtained by first swelling the contact lens in isopropyl alcohol, removing the lens from the alcoholic solution and dipping it into an aqueous solution comprising the polyanionic and polycationic component.
  • the above-mentioned coating processes are in general batch processes, which require extensive handling steps and time.
  • the treatment is usually performed at an elevated temperature, and the treatment times are at least several minutes and in general at least an hour and more. In case the treatment times are shortened, unsatisfactory results are obtained due to an insufficient surface coverage with the ionic component(s). Because of this, none of the existing processes is well suited, for example, for the integration into a fully automated high volume contact lens manufacturing process with short cycle times as described, for example, in EP-A-969956 or EP-A-1047542.
  • hydrophobic biomedical articles such as silicon-containing contact lenses may be rendered effectively hydrophilic in a very short time by treating the articles in a substantially anhydrous solution of a polyanionic compound.
  • the present invention therefore in one aspect concerns a process for the hydrophilic coating of a biomedical article, which comprises treating the biomedical article for a time period of ⁇ 5 minutes with a solution of an organic solvent comprising a polyanionic compound with a number average molecular weight M n of >5000, wherein the solution comprises less than 10% by weight of water.
  • the biomedical article according to the invention is, for example, an ophthalmic device, preferably a contact lens including both hard and particularly soft contact lenses, an intraocular lens or an artificial cornea, comprising in each case an organic bulk material.
  • suitable biomedical articles are wound healing dressings, eye bandages, materials for the sustained release of an active compound such as a drug delivery patch, moldings that can be used in surgery, such as heart valves, vascular grafts, catheters, artificial organs, encapsulated biologic implants, e.g. pancreatic islets, materials for prostheses such as bone substitutes, or moldings for diagnostics, membranes or biomedical instruments or apparatus.
  • the organic bulk material underlying the biomedical article is preferably a hydrophobic material that is devoid of ionic groups such as cationic or anionic groups or has at least a relatively low concentration of ionic groups. Accordingly, the surface of the preferred bulk materials also has a low concentration of ionic groups or is even devoid of ionic groups such as carboxy, sulfo, amino and the like groups and thus may be substantially free of ionic charges.
  • suitable bulk materials are natural or synthetic organic polymers or modified biopolymers which are known in large number.
  • polymers are polyaddition and polycondensation polymers (polyurethanes, epoxy resins, polyethers, polyesters, polyamides and polyimides); vinyl polymers (polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polystyrene, polyethylene and halogenated derivatives thereof, polyvinyl acetate and polyacrylonitrile); or elastomers (silicones, polybutadiene and polyisoprene).
  • a preferred group of materials to be coated are those being conventionally used for the manufacture of biomedical devices, e.g. contact lenses, in particular contact lenses for extended wear, which are not hydrophilic per se.
  • Such materials are known to the skilled artisan and may comprise for example polysiloxanes, perfluoroalkyl polyethers, fluorinated poly(meth)acrylates, polyalkyl (meth)acrylates, or fluorinated polyolefines, such as fluorinated ethylene or propylene, for example tetrafluoroethylene, preferably in combination with specific dioxols, such as perfluoro-2,2-dimethyl-1,3-dioxol. Mixtures of two or more of the above-mentioned materials are also possible.
  • silicon hydrogels are the preferred hydrophobic organic bulk materials.
  • suitable silicon hydrogels are, for example, those currently used for the manufacture of extended wear contact lenses, for example copolymers of (i) one or more hydrophilic monomers, for example selected from the group of hydroxyethylacrylate, hydroxyethylmethacrylate, acrylamide, N,N-dimethyl acrylamide, a vinyl lactame such as N-vinylpyrrolidone, a (meth)acryloyloxyethyl phosphorylcholine, such as 2-acryloyloxyethyl phosphorylcholine or 2-methacryloyloxyethyl-2′-(trimethylammonium)ethyl phosphoryl-choline, N-vinyloxycarbonyl-L-alanine, acrylic or methacrylic acid; and (ii) a monomer and/or macromonomer comprising a siloxane bond or silane group, e.g.
  • trimethylsilyl group examples of the latter group are tris-trimethylsilyloxy-silyl-propyl methacrylate (TRIS) or tris-trimethylsilyloxy-silyl-propyl vinyl carbamate (TRIS-VC), a polydimethylsiloxane having a carbon-carbon double bond at one single terminal, or a polydimethylsiloxane crosslinker having either a carbon-carbon double bond at both terminals or two or more pendent C—C double bonds, for example, as described in formula (2) below.
  • suitable commercially available silicon hydrogels are Balafilcon A, Galyfilcon A, Lotrafilcon A, Lotrafilcon B or Senofilcon A.
  • silicon hydrogels are amphiphilic segmented copolymers comprising at least one hydrophobic silicon or perfluoroalkyl polyether segment and at least one hydrophilic segment which are linked through a bond or a bridge member.
  • Examples of said silicon hydrogels are disclosed, for example, in PCT applications WO 96/31792 and WO 97/49740 which are herewith incorporated by reference.
  • a particularly preferred amphiphilic segmented copolymer comprises at least one hydrophobic segment selected from the group consisting of a polysiloxane, perfluoroalkyl polyether and a mixed polysiloxane/perfluoroalkyl polyether segment, and at least one hydrophilic segment selected from the group consisting of a polyoxazoline, poly(2-hydroxyethylacrylate), poly(2-hydroxyethylmethacrylate), polyacrylamide, poly(N,N-dimethylacrylamide), polyvinylpyrrolidone and a polyethyleneoxide segment.
  • Still another group of preferred silicon hydrogels are those obtainable by crosslinking a crosslinkable or polymerizable prepolymer that is obtainable by
  • a particularly preferred silicon hydrogel is obtained by crosslinking a prepolymer which is obtainable by
  • R 1 is hydrogen or methyl
  • R 2 is —COO—(CH 2 ) 2 —OH, —CONH 2 , —CON(CH 3 ) 2 ,
  • d 1 is an integer from 10 to 500, preferably 10 to 300, more preferably 20 to 200 and in particular 25 to 150
  • (alk) is linear or branched C 2 -C 4 alkylene or a radical —(CH 2 ) 1-3 —O—(CH 2 ) 1-3 -
  • X is —O— or —NH—
  • Q is a radical of the formula
  • a chain transfer agent having a functional group in particular 2-mercapto-ethanol or especially 2-aminoethane thiol (cysteamine); and (b) reacting the resulting copolymer with an organic compound having an ethylenically unsaturated group, for example with 2-isocyanatoethylmethacrylate (IEM), 2-vinyl-azlactone, 2-vinyl-4,4-dimethyl-azlactone, acryloyl or methacryloyl chloride, 2-hydroxyethylacrylate (HEA), 2-hydroxymethacrylate (HEMA), glycidylacrylate or glycidylmethacrylat, in particular with IEM or acryloyl chloride.
  • IEM 2-isocyanatoethylmethacrylate
  • HAA 2-hydroxyethylacrylate
  • HEMA 2-hydroxymethacrylate
  • glycidylacrylate or glycidylmethacrylat in particular with IEM or
  • the polyanionic compound employed in the process of the invention is preferably a carboxyl functional polymer, that is a polymer having carboxyl groups.
  • suitable carboxyl functional polymers are a polyacrylic acid; a polymethacrylic acid; a polyitaconic acid; a copolymer of two or more different carboxyl functional monomers, for example selected from the group consisting of acrylic acid, methacrylic acid, maleic acid, maleic anhydride and itaconic acid; or a copolymer of one or more carboxylic acids, for example, of the group acrylic acid, methacrylic acid, maleic acid, maleic anhydride and itaconic acid and one or more suitable non-ionic vinyl monomers, for example, of the group N-vinylpyrrolidone, methylvinylether, acrylamide, N,N-dimethylacrylamide, vinyl acetate, HEA. HEMA and a monovinyl polyethylene oxide; the above term copolymer is also meant to cover
  • the polyanionic compound is a polyacrylic acid or a copolymer of acrylic acid and one of the above mentioned further carboxyl functional monomers or non-ionic monomers, in particular a polyacrylic acid.
  • the number average molecular weight Mn of the polyanionic compound is >5000, preferably ⁇ 15000 and more preferably ⁇ 20000.
  • the upper limit of M n is in general not critical, anionic polymers being suitable up to a number average molecular weight of 1 million or above. Accordingly, a number average molecular weight M n of the polyanionic compound of from 7500 to 1.3 million, preferably from 7500 to 1 million, more preferably from 20000 to 1 million, even more preferably from 20000 to 750000, and in particular from 80000 to 500000, has proven as valuable.
  • a suitable organic solvent for the polyanionic compound is in principle every solvent with the ability to swell the organic bulk material underlying the biomedical article.
  • Preferred solvents are, for example, alcohols, for example a C 2 -C 4 -alcohol, in particular ethanol or n- or isopropanol, especially ethanol; glycol ethers, for example a diethyleneglycol mono-C 1 -C 4 -alkylether, in particular diethyleneglycol monomethyl ether, diethyleneglycol monoethyl ether (DEGME), diethyleneglycol diethyl ether or diethyleneglycol monobutyl ether.
  • DEGME diethyleneglycol monoethyl ether
  • the preferred organic solvent is ethanol. It is also possible to use a mixture of two or more of the above-mentioned organic solvents. The presence of water severely affects the efficiency of the process and therefore should be limited as much as possible. Accordingly, it is preferred to employ a solution into the process comprising less than 20%, preferably less than 10%, more preferably less than 5%, and in particular less than 2% of water.
  • the solution of the polyanionic compound for treatment of the biomedical article in general has an acidic pH value; the preferred pH value is ⁇ 5, more preferably ⁇ 4, even more preferably from 1.5 to 3.5, and in particular from 1.8 to 3.
  • the solution for treatment of the biomedical article is devoid of a cationic polymer.
  • the concentration of the polyanionic compound in the organic solvent is, for example from 0.1 to 25 g/l, preferably from 1 to 15 g/l, and most preferably from 3 to 10 g/l of solvent.
  • a preferred treatment solution according to the present invention is a solution of a polyacrylic acid or a copolymer of acrylic acid and a comonomer selected from the group consisting of methacrylic acid, maleic acid, maleic anhydride, itaconic acid, N-vinylpyrrolidone, methylvinylether, acrylamide, N,N-dimethylacrylamide and a monovinyl polyethylene oxide, in a C 2 -C 4 -alcohol or diethyleneglycol mono-C 1 -C 4 -alkylether, wherein the number average molecular weight M n of the polyacrylic acid homo- or copolymer is from 7500 to 1 million, and wherein the pH value of the solution is ⁇ 4.
  • a more preferred treatment solution according to the present invention is a solution of a polyacrylic acid having a number average molecular weight M n of from 20000 to 750000 in ethanol, wherein the pH value of the solution is from 1.5 to 3.5 and in particular from 1.8 to 3.
  • the treatment solutions of the present invention may be prepared in a manner known per se, for example by simple mixing of the ingredients, which are likewise known per se and in general commercially available.
  • the pH adjustment towards more acidic pH values may be performed, for example, by the addition of gaseous HCl.
  • Certain solutions of anhydrous acids in organic solvents, such as ethanol/HCl, are also commercially available.
  • the treatment of the biomedical article with the treatment solution is suitably performed under ambient conditions or at an elevated temperature depending on the solvent used.
  • a temperature of from 10 to 50° C., preferably from 15 to 45° C. is employed.
  • room temperature that is a temperature of, for example, from 10 to 35° C. and preferably from 15 to 25° C. is preferably used for the treatment.
  • the treatment may be accomplished according to processes known per se.
  • the biomedical article is immersed in the treatment solution, or the treatment solution is deposited on the biomedical article surface, for example, by dipping, spraying, printing, spreading, pouring, rolling or spin coating, spraying or particularly dipping being preferred.
  • the treatment takes place for a time period of ⁇ 5 minutes, preferably ⁇ 1 minute, more preferably ⁇ 30 seconds and in particular ⁇ 10 seconds.
  • the biomedical article is removed from the treatment solution and worked up, for example, as described below.
  • Suitable solvents for this follow-up step are, for example, water, ethylene glycol, glycerol, 1,3-propanediol, or mixtures thereof.
  • a preferred solvent for the follow-up step is water.
  • the biomedical article—following its removal from the treatment solution is dipped/immersed directly into the solution.
  • the time period for the follow-up step is not critical; usually a time period of ⁇ 1 minute, preferably ⁇ 30 seconds more preferably ⁇ 10 seconds is sufficient to accomplish the shrinkage of the bulk material.
  • the biomedical article is treated with an aqueous solution comprising a neutral or slightly basic pH, for example a pH value of 7 to 10, preferably from 7.5 to 10, and in particular from 7.5 to 9.5.
  • the aqueous solution advantageously may contain further ingredients, for example a salt, in particular sodium chloride, or a suitable buffer, for example a phosphate buffer.
  • the preferred treatment is again dipping/immersing the biomedical article into the aqueous solution.
  • the time period for this additional neutralization step is again not critical; usually a time period of ⁇ 1 minute, preferably ⁇ 30 seconds more preferably ⁇ 10 seconds is sufficient to accomplish a further improvement of the surface coating.
  • shrinkage and neutralization may be done in one step by dipping the biomedical article in an aqueous solution of a weak base having a pH of, for example, from 7.5 to 10, for example in an aqueous NaHCO 3 or the like solution.
  • the biomedical article then may be worked up and finished in a usual manner.
  • contact lenses are in general subjected to a sterilization step, which comprises, for example, autoclaving the contact lenses for a certain time period at an elevated temperature.
  • a sterilization step comprises, for example, autoclaving the contact lenses for a certain time period at an elevated temperature.
  • autoclaving for a time period of 20 minutes to 1.5 hours, in particular from 30 minutes to 1 hour, at a temperature of about 115 to 130° C. has proven as valuable.
  • biomedical articles in particular ophthalmic articles
  • ophthalmic articles are obtained that have a variety of unexpected advantages over those of the prior art, which make those articles very suitable for practical purposes, e.g. as contact lens for extended wear.
  • they do have a high surface wettability and lubricity.
  • This can be demonstrated, for example, by the finger tip test showing a very slippery article surface; or by visual inspection; or by suitable contact angle measurements.
  • sessile drop static contact angles of coated and non-coated lenses are determined with a DSA 10 drop shape analysis system from Krüss (Krüss GmbH, Hamburg, Germany).
  • uncoated silicon hydrogel contact lenses in general have a water contact angle of 90 to 100° or above, a treatment according to the process of the invention significantly reduces said value.
  • Further tools for assessing the superior quality of the surface coatings obtainable according to the process of the invention are ATR-FTIR measurements or the Sudan Black dye absorption test as described below in the Examples section.
  • biomedical devices e.g. ophthalmic devices such as contact lenses
  • a composite material of the invention have a very pronounced biocompatibility combined with good mechanical properties.
  • ophthalmic devices such as contact lenses
  • good mechanical properties can be for example found in a low friction coefficient and low abrasion properties.
  • the dimensional stability of the composite materials of the invention is excellent.
  • the attachment of a hydrophilic surface coating at a given bulk material according to the invention does not affect its visual transparency.
  • biomedical articles such as contact lenses may be coated very fast, that is within seconds; nevertheless the coated articles are mechanically very stable and robust. No pre-treatment step or the like is necessary, the lenses may be coated directly following their manufacture. This makes the process of the invention highly adaptable into a high volume mass production process, such as the contact lens manufacturing process as disclosed in EP-A-969956 or EP-A-1047542.
  • the surface treatment according to the present invention in general does not affect the properties of the underlying organic bulk material. While prior art coating processes often affect article properties such as transparency, ion permeability, oxygen transmissibility, water contents or device geometry (e.g. diameter of a contact lens), said parameters are not or at least not significantly affected by the process of the invention.
  • a 4-L beaker 24.13 g of Na 2 CO 3 , 80 g of NaCl and 1.52 kg of deionized water are mixed to dissolve.
  • a separate 4-L beaker 700 g of bis-3-aminopropyl-polydimethylsiloxane (Shin-Etsu, MW ca. 11500) are dissolved in 1000 g of hexane.
  • a 4-L reactor is equipped with overhead stirring with turbine agitator and a 250-mL addition funnel with micro-flow controller. The two solutions are then charged to the reactor, and mixed for 15 minutes with heavy agitation to produce an emulsion.
  • a 4-L beaker 61.73 g of Na 2 CO 3 , 80 g of NaCl and 1.52 kg of deionized water are mixed to dissolve.
  • a separate 4-L beaker 700 g of bis-3-aminopropyl-polydimethylsiloaxane (Shin-Etsu, MW ca. 4500) are dissolved in 1000 g of hexane.
  • a 4-L reactor is equipped with overhead stirring with turbine agitator and a 250-mL addition funnel with micro-flow controller. The two solutions are then charged to the reactor, and mixed for 15 minutes with heavy agitation to produce an emulsion.
  • a 2-L jacketed reactor is equipped with a heating/chilling loop, reflux condenser, N 2 -inlet/vacuum adapter, feeding tube adapter and overhead mechanical stirring.
  • a solution is generated by dissolving 90.00 g of PDMS crosslinker I according to (ia) and 30.00 g of PDMS crosslinker II according to (ib) in 480 g of 1-propanol. This solution is charged to the reactor and cooled to 8° C. The solution is degassed by evacuating to less than 15 mBar, holding at vacuum for 15 minutes, and then re-pressurizing with dry nitrogen. This degas procedure is repeated for a total of 3 times. The reactor is held under a blanket of dry nitrogen.
  • a monomer solution is prepared by mixing 1.50 g of cysteamine hydrochloride, 0.3 g of AIBN, 55.275 g of DMA, 18.43 g of HEA and 364.5 g of 1-propanol. This solution is filtered with a Waterman 540 filter paper, and then added to the reactor through a degas unit and HPLC pump with a flow rate of 3.0 mL /minute. The reaction temperature is then elevated to 68° C. with a heating ramp about one hour.
  • a feeding solution is prepared by mixing 4.5 g of cysteamine hydrochloride and 395.5 g of 1-propanol and then filtering with Waterman 540 filter paper. When the reactor temperature reaches 68° C., this solution is slowly dosed into the reactor through the degasser/HPLC pump over 3 hours. The reaction is then continued at 68° C. for an additional 3 hours, on which heating has discontinued and the reactor is allowed to cool to room temperature.
  • reaction mixture is transferred to a flask and stripped solvent at 40° C. under vacuum on a rotary evaporator until 1000 g of sample remained.
  • the solution is then slowly mixed with 2000 g of deionized water with rapid agitation. Additional solvent is further removed until about 2000 g of sample remain. During this stripping process, the solution gradually becomes an emulsion.
  • the resulting material is purified by ultrafiltration over a 10 kD molecular weight cut-off membrane until the permeate conductance is below 2.5 ⁇ S/cm.
  • This emulsion is then charged to a 2-L reactor equipped with overhead stirring, refrigeration loop, thermometer, and the pH meter and dispensing tip of a Metrohm Model 718 STAT Titrino.
  • the reaction mixture is then cooled to 1° C. 7.99 g of NaHCO 3 are charged to the emulsion and stirred to dissolve.
  • the Titrino is set to maintain pH at 9.5 by intermittent addition of 15% sodium hydroxide solution. 11.59 mL of acryloyl chloride are then added over one hour using a syringe pump.
  • the emulsion is stirred for another hour, then the Titrino is set to neutralize the reaction mixture by addition of a 15% solution of hydrochloric acid.
  • the product is purified by ultrafiltration again with 10 kD molecular weight cut-off membrane until the permeate conductance is below 2.5 ⁇ S/cm.
  • the final macromonomer is isolated by lypophilization.
  • step (ic) 18.83 g of the polymer obtained according to step (ic) are dissolved in approximately 200 mL of 1-propanol, concentrated to ca. 70 g total solution weight, and filtered to 0.45 ⁇ m exclusion. 67.94 g of solution at 26.53% solids are recovered. 4.503 g of a 1% solution of 2-hydroxy-4′-hydroxyethyl-2-methylpropiophenone (IRGACURE®-2959, Ciba Specialty Chemicals) are added, and the solution is then concentrated to a final formulation having 60% solids.
  • IRGACURE®-2959 2-hydroxy-4′-hydroxyethyl-2-methylpropiophenone
  • 200 mg of the formulation are dosed into poly(propylene) contact lens molds and the molds are closed.
  • the molds are then irradiated for 15 s with an ultraviolet light source having an intensity of 2.18 mW/cm 2 .
  • the molds are then opened, and the contact lenses are removed from the mold halves.
  • a hydrophobic silicon hydrogel contact lens obtained according to (id) above is placed on a lens holder.
  • the lens holder with the lens is then immersed at room temperature for 5 sec into the treatment solution obtained according to Example 1.
  • the lens holder with the lens is rinsed for 2 sec in a water bath and subsequently treated for 2 sec in a phosphate buffered saline (pH 7.2).
  • the contact lens is then transferred into a glass vial and sterilized for 30 min at 121° C. by autoclaving.
  • the presence of the polyacrylic acid coating is proven by ATR-FTIR spectroscopy (absorption at 1720 cm ⁇ 1 at pH 2 and at 1560-1620 cm ⁇ 1 at pH 7.2).
  • the hydrophilic surface coating is further investigated by visual wettability and hydrophilicity testing as well as contact angle measurements and the Sudan Black staining test (see Table I below).
  • Hydrophobic silicon hydrogel contact lenses (lotrafilcon A, copolymerization product of a mixed polysiloxane/perfluoroalkyl polyether crosslinker, TRIS and DMA) are subjected to the surface treatment as described in Example 2 (ie). The results are summarized in Table I below.
  • Hydrophobic silicon hydrogel contact lenses (lotrafilcon B, copolymerization product of a mixed polysiloxane/ perfluoroalkyl polyether crosslinker, TRIS and DMA) are subjected to the surface treatment as described in Example 2 (ie). The results are summarized in Table I below.
  • Hydrophobic silicon hydrogel contact lenses (galyfilcon, commercially available under the brand name Acuvue Advance®) are first of all extracted with 2-propanol (2 ml/lens), then rinsed with water several times and stored in a vessel in cold water.
  • Example 2 For coating purposes a contact lens is taken directly out of the vessel and is subjected to the surface treatment as described in Example 2 (ie). The results are summarized in Table I below.
  • the ranking is based on the observation, how fast a film of the storage solution on the surface of the autoclaved contact lens vanishes following the removal of the lens from the storage vial with tweezers.
  • the measurement is performed by the sessile drop method with a DSA 10 drop shape analysis system from Krüss GmbH, Germany with pure water (Fluka, surface tension 72.5 mN/M at 20° C.).
  • a contact lens is taken off the storage solution with tweezers and excess storage solution is removed by gentle shaking.
  • the contact lens is placed on the male part of a contact lens mold and gently blotted with a dry and clean cloth.
  • ATR-FTIR measurements are performed with a Nicolet FTIR spectrometer equipped with a ZnSe crystal in an overhead sample holder (45° angle of incidence) with micrometer controlled clamp-down facility.
  • a dried contact lens vacuum drying oven, 1 mbar, 25° C., 30 min
  • the ATR-Infrared absorbance spectra are all normalized to the signal at 2961 cm ⁇ 1 ; assessment by comparison of the signal increase at 1720 cm ⁇ 1 (v COOH ) with the signal at about 1631 cm ⁇ 1 ( indicative for silicon hydrogel presence).
  • a 0.5% (w/w) Sudan Black dye solution is prepared by dissolving 0.5 g of Sudan Black B (Aldrich) over night in 100 g of vitamin E oil under stirring.
  • the surface-treated lens is first of all autoclaved (30 min, 121° C.) in 2 ml of an phosphate buffered saline (pH 7.2) in a glass vial.
  • the contact lens is then removed from the solution with tweezers and gently shaken so that most of the surface water is removed.
  • the lens is then placed in the above prepared Sudan Black dye solution for 5 min. Thereafter the lens is removed from the dye-bath, and the excess dye solution is rinsed off with warm water.
  • the lens is air-dried and assessed according to its degree of staining.
  • Lens Coating Process The lens coating processes are performed with Lotrafilcon B lenses as described in Example 2 (ie) by variation of the treatment time (5 s, 10s, 30 s, 60 s and 300 s) and water content of the treatment solution cH20 (0%, 5%, 20%, 50% and 100%).
  • Lens Surface Characterizations are performed with Lotrafilcon B lenses as described in Example 2 (ie) by variation of the treatment time (5 s, 10s, 30 s, 60 s and 300 s) and water content of the treatment solution cH20 (0%, 5%, 20%, 50% and 100%).
  • Lenses were evaluated and characterized by water contact angle, slipperiness, and Sudan Black staining test according to the methods described in Example 6.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Eyeglasses (AREA)
  • Materials For Medical Uses (AREA)
  • Surface Treatment Of Optical Elements (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Paints Or Removers (AREA)

Abstract

The invention relates to a process for the manufacture of a hydrophilic coating on a biomedical article, which comprises treating the biomedical article for a time period of ≦5 minutes with a solution of an organic solvent comprising a polyanionic compound with a number average molecular weight Mn of >5000, wherein the solution comprises less than 10% by weight of water, and wherein the solution is devoid of a cationic polymer. The coated biomedical articles obtainable by the process of the invention have desirable characteristics regarding adherence to the substrate, durability, hydrophilicity, wettability, biocompatibility and permeability and are thus especially useful in the field of ophthalmic devices.

Description

  • The present invention relates to a process for the manufacture of coated articles such as biomedical articles, especially contact lenses, which are at least partly coated with a polyanionic polymer.
  • A variety of different types of processes for preparing coatings on an “inert” hydrophobic article, in particular on an inert biomedical article such as a silicon hydrogel containing contact lens, have been disclosed in the prior art. EP-A 1 153 964 and EP-A-1 287 060 both disclose polyanionic coatings on silicon hydrogel contact lenses, which are prepared by immersing the contact lenses in an aqueous solution of the polyanionic compound. EP-A 1 252 222 discloses in Example 7 a silicon hydrogel lens coated with a polyacrylic acid and a polyallylamine in a molar ratio of 10:1; the coating is obtained by first swelling the contact lens in isopropyl alcohol, removing the lens from the alcoholic solution and dipping it into an aqueous solution comprising the polyanionic and polycationic component.
  • The above-mentioned coating processes are in general batch processes, which require extensive handling steps and time. The treatment is usually performed at an elevated temperature, and the treatment times are at least several minutes and in general at least an hour and more. In case the treatment times are shortened, unsatisfactory results are obtained due to an insufficient surface coverage with the ionic component(s). Because of this, none of the existing processes is well suited, for example, for the integration into a fully automated high volume contact lens manufacturing process with short cycle times as described, for example, in EP-A-969956 or EP-A-1047542.
  • Accordingly, there is a need to provide an improved process for the hydrophilic coating of a biomedical article with a polyanionic compound, which is on the one hand easily integrable in a mass manufacturing process and on the other hand provides hydrophilic coatings with an improved durability and wearer comfort.
  • Surprisingly, it has now been found, that hydrophobic biomedical articles such as silicon-containing contact lenses may be rendered effectively hydrophilic in a very short time by treating the articles in a substantially anhydrous solution of a polyanionic compound.
  • The present invention therefore in one aspect concerns a process for the hydrophilic coating of a biomedical article, which comprises treating the biomedical article for a time period of ≦5 minutes with a solution of an organic solvent comprising a polyanionic compound with a number average molecular weight Mn of >5000, wherein the solution comprises less than 10% by weight of water.
  • The biomedical article according to the invention is, for example, an ophthalmic device, preferably a contact lens including both hard and particularly soft contact lenses, an intraocular lens or an artificial cornea, comprising in each case an organic bulk material. Further examples of suitable biomedical articles are wound healing dressings, eye bandages, materials for the sustained release of an active compound such as a drug delivery patch, moldings that can be used in surgery, such as heart valves, vascular grafts, catheters, artificial organs, encapsulated biologic implants, e.g. pancreatic islets, materials for prostheses such as bone substitutes, or moldings for diagnostics, membranes or biomedical instruments or apparatus.
  • The organic bulk material underlying the biomedical article is preferably a hydrophobic material that is devoid of ionic groups such as cationic or anionic groups or has at least a relatively low concentration of ionic groups. Accordingly, the surface of the preferred bulk materials also has a low concentration of ionic groups or is even devoid of ionic groups such as carboxy, sulfo, amino and the like groups and thus may be substantially free of ionic charges.
  • Examples of suitable bulk materials are natural or synthetic organic polymers or modified biopolymers which are known in large number. Some examples of polymers are polyaddition and polycondensation polymers (polyurethanes, epoxy resins, polyethers, polyesters, polyamides and polyimides); vinyl polymers (polyacrylates, polymethacrylates, polyacrylamides, polymethacrylamides, polystyrene, polyethylene and halogenated derivatives thereof, polyvinyl acetate and polyacrylonitrile); or elastomers (silicones, polybutadiene and polyisoprene).
  • A preferred group of materials to be coated are those being conventionally used for the manufacture of biomedical devices, e.g. contact lenses, in particular contact lenses for extended wear, which are not hydrophilic per se. Such materials are known to the skilled artisan and may comprise for example polysiloxanes, perfluoroalkyl polyethers, fluorinated poly(meth)acrylates, polyalkyl (meth)acrylates, or fluorinated polyolefines, such as fluorinated ethylene or propylene, for example tetrafluoroethylene, preferably in combination with specific dioxols, such as perfluoro-2,2-dimethyl-1,3-dioxol. Mixtures of two or more of the above-mentioned materials are also possible.
  • Within the present invention silicon hydrogels, perfluoroalkyl polyethers or mixtures thereof, in particular silicon hydrogels, are the preferred hydrophobic organic bulk materials.
  • Examples of suitable silicon hydrogels are, for example, those currently used for the manufacture of extended wear contact lenses, for example copolymers of (i) one or more hydrophilic monomers, for example selected from the group of hydroxyethylacrylate, hydroxyethylmethacrylate, acrylamide, N,N-dimethyl acrylamide, a vinyl lactame such as N-vinylpyrrolidone, a (meth)acryloyloxyethyl phosphorylcholine, such as 2-acryloyloxyethyl phosphorylcholine or 2-methacryloyloxyethyl-2′-(trimethylammonium)ethyl phosphoryl-choline, N-vinyloxycarbonyl-L-alanine, acrylic or methacrylic acid; and (ii) a monomer and/or macromonomer comprising a siloxane bond or silane group, e.g. trimethylsilyl group. Examples of the latter group are tris-trimethylsilyloxy-silyl-propyl methacrylate (TRIS) or tris-trimethylsilyloxy-silyl-propyl vinyl carbamate (TRIS-VC), a polydimethylsiloxane having a carbon-carbon double bond at one single terminal, or a polydimethylsiloxane crosslinker having either a carbon-carbon double bond at both terminals or two or more pendent C—C double bonds, for example, as described in formula (2) below. Examples of suitable commercially available silicon hydrogels are Balafilcon A, Galyfilcon A, Lotrafilcon A, Lotrafilcon B or Senofilcon A.
  • Another group of preferred silicon hydrogels are amphiphilic segmented copolymers comprising at least one hydrophobic silicon or perfluoroalkyl polyether segment and at least one hydrophilic segment which are linked through a bond or a bridge member. Examples of said silicon hydrogels are disclosed, for example, in PCT applications WO 96/31792 and WO 97/49740 which are herewith incorporated by reference. A particularly preferred amphiphilic segmented copolymer comprises at least one hydrophobic segment selected from the group consisting of a polysiloxane, perfluoroalkyl polyether and a mixed polysiloxane/perfluoroalkyl polyether segment, and at least one hydrophilic segment selected from the group consisting of a polyoxazoline, poly(2-hydroxyethylacrylate), poly(2-hydroxyethylmethacrylate), polyacrylamide, poly(N,N-dimethylacrylamide), polyvinylpyrrolidone and a polyethyleneoxide segment.
  • Still another group of preferred silicon hydrogels are those obtainable by crosslinking a crosslinkable or polymerizable prepolymer that is obtainable by
  • (a) copolymerizing at least one hydrophilic monomer having one ethylenically unsaturated double bond and at least one silicon crosslinker comprising two or more ethylenically unsaturated double bonds in the presence of a chain transfer agent having a functional group; and
    (b) reacting one or more functional groups of the resulting copolymer with an organic compound having an ethylenically unsaturated group. Silicon hydrogels of this type are disclosed, for example in WO 01/71392 which is herewith incorporated by reference.
  • A particularly preferred silicon hydrogel is obtained by crosslinking a prepolymer which is obtainable by
  • (a) copolymerizing a hydrophilic monomer of the formula
  • Figure US20080152800A1-20080626-C00001
  • wherein R1 is hydrogen or methyl, and R2 is —COO—(CH2)2—OH, —CONH2, —CON(CH3)2,
  • Figure US20080152800A1-20080626-C00002
  • optionally in admixture with one or more further hydrophilic monomers; and a polysiloxane crosslinker that corresponds to formula
  • Figure US20080152800A1-20080626-C00003
  • wherein d1 is an integer from 10 to 500, preferably 10 to 300, more preferably 20 to 200 and in particular 25 to 150, (alk) is linear or branched C2-C4 alkylene or a radical —(CH2)1-3—O—(CH2)1-3-, X is —O— or —NH— and Q is a radical of the formula
  • Figure US20080152800A1-20080626-C00004
  • in the presence of a chain transfer agent having a functional group, in particular 2-mercapto-ethanol or especially 2-aminoethane thiol (cysteamine); and
    (b) reacting the resulting copolymer with an organic compound having an ethylenically unsaturated group, for example with 2-isocyanatoethylmethacrylate (IEM), 2-vinyl-azlactone, 2-vinyl-4,4-dimethyl-azlactone, acryloyl or methacryloyl chloride, 2-hydroxyethylacrylate (HEA), 2-hydroxymethacrylate (HEMA), glycidylacrylate or glycidylmethacrylat, in particular with IEM or acryloyl chloride.
  • The polyanionic compound employed in the process of the invention is preferably a carboxyl functional polymer, that is a polymer having carboxyl groups. Examples of suitable carboxyl functional polymers are a polyacrylic acid; a polymethacrylic acid; a polyitaconic acid; a copolymer of two or more different carboxyl functional monomers, for example selected from the group consisting of acrylic acid, methacrylic acid, maleic acid, maleic anhydride and itaconic acid; or a copolymer of one or more carboxylic acids, for example, of the group acrylic acid, methacrylic acid, maleic acid, maleic anhydride and itaconic acid and one or more suitable non-ionic vinyl monomers, for example, of the group N-vinylpyrrolidone, methylvinylether, acrylamide, N,N-dimethylacrylamide, vinyl acetate, HEA. HEMA and a monovinyl polyethylene oxide; the above term copolymer is also meant to cover suitable block copolymers.
  • Preferably, the polyanionic compound is a polyacrylic acid or a copolymer of acrylic acid and one of the above mentioned further carboxyl functional monomers or non-ionic monomers, in particular a polyacrylic acid.
  • The number average molecular weight Mn of the polyanionic compound is >5000, preferably ≧15000 and more preferably ≧20000. The upper limit of Mn is in general not critical, anionic polymers being suitable up to a number average molecular weight of 1 million or above. Accordingly, a number average molecular weight Mn of the polyanionic compound of from 7500 to 1.3 million, preferably from 7500 to 1 million, more preferably from 20000 to 1 million, even more preferably from 20000 to 750000, and in particular from 80000 to 500000, has proven as valuable.
  • A suitable organic solvent for the polyanionic compound is in principle every solvent with the ability to swell the organic bulk material underlying the biomedical article. Preferred solvents are, for example, alcohols, for example a C2-C4-alcohol, in particular ethanol or n- or isopropanol, especially ethanol; glycol ethers, for example a diethyleneglycol mono-C1-C4-alkylether, in particular diethyleneglycol monomethyl ether, diethyleneglycol monoethyl ether (DEGME), diethyleneglycol diethyl ether or diethyleneglycol monobutyl ether.
  • The preferred organic solvent is ethanol. It is also possible to use a mixture of two or more of the above-mentioned organic solvents. The presence of water severely affects the efficiency of the process and therefore should be limited as much as possible. Accordingly, it is preferred to employ a solution into the process comprising less than 20%, preferably less than 10%, more preferably less than 5%, and in particular less than 2% of water.
  • The solution of the polyanionic compound for treatment of the biomedical article in general has an acidic pH value; the preferred pH value is ≦5, more preferably ≦4, even more preferably from 1.5 to 3.5, and in particular from 1.8 to 3.
  • The solution for treatment of the biomedical article is devoid of a cationic polymer.
  • In general, rather diluted solutions of the polyanionic compound are employed in the process of the invention. Accordingly, the concentration of the polyanionic compound in the organic solvent is, for example from 0.1 to 25 g/l, preferably from 1 to 15 g/l, and most preferably from 3 to 10 g/l of solvent.
  • A preferred treatment solution according to the present invention is a solution of a polyacrylic acid or a copolymer of acrylic acid and a comonomer selected from the group consisting of methacrylic acid, maleic acid, maleic anhydride, itaconic acid, N-vinylpyrrolidone, methylvinylether, acrylamide, N,N-dimethylacrylamide and a monovinyl polyethylene oxide, in a C2-C4-alcohol or diethyleneglycol mono-C1-C4-alkylether, wherein the number average molecular weight Mn of the polyacrylic acid homo- or copolymer is from 7500 to 1 million, and wherein the pH value of the solution is ≦4.
  • A more preferred treatment solution according to the present invention is a solution of a polyacrylic acid having a number average molecular weight Mn of from 20000 to 750000 in ethanol, wherein the pH value of the solution is from 1.5 to 3.5 and in particular from 1.8 to 3.
  • The treatment solutions of the present invention may be prepared in a manner known per se, for example by simple mixing of the ingredients, which are likewise known per se and in general commercially available. The pH adjustment towards more acidic pH values may be performed, for example, by the addition of gaseous HCl. Certain solutions of anhydrous acids in organic solvents, such as ethanol/HCl, are also commercially available.
  • The treatment of the biomedical article with the treatment solution is suitably performed under ambient conditions or at an elevated temperature depending on the solvent used. For example, a temperature of from 10 to 50° C., preferably from 15 to 45° C. is employed. In case of water as the solvent, room temperature, that is a temperature of, for example, from 10 to 35° C. and preferably from 15 to 25° C. is preferably used for the treatment.
  • The treatment may be accomplished according to processes known per se. For example, the biomedical article is immersed in the treatment solution, or the treatment solution is deposited on the biomedical article surface, for example, by dipping, spraying, printing, spreading, pouring, rolling or spin coating, spraying or particularly dipping being preferred.
  • The treatment takes place for a time period of ≦5 minutes, preferably ≦1 minute, more preferably ≦30 seconds and in particular ≦10 seconds. Following the treatment with the polyanionic compound, the biomedical article is removed from the treatment solution and worked up, for example, as described below.
  • According to a preferred embodiment of the invention, the biomedical article—following its removal from the treatment solution—is contacted with a solvent, which has the ability to shrink the organic bulk material underlying the biomedical article, but which is miscible with the solvent of the treatment solution. Suitable solvents for this follow-up step are, for example, water, ethylene glycol, glycerol, 1,3-propanediol, or mixtures thereof. A preferred solvent for the follow-up step is water. Preferably, the biomedical article—following its removal from the treatment solution is dipped/immersed directly into the solution. The time period for the follow-up step is not critical; usually a time period of ≦1 minute, preferably ≦30 seconds more preferably ≦10 seconds is sufficient to accomplish the shrinkage of the bulk material.
  • It is further preferred that following the shrinkage step the biomedical article is treated with an aqueous solution comprising a neutral or slightly basic pH, for example a pH value of 7 to 10, preferably from 7.5 to 10, and in particular from 7.5 to 9.5. The aqueous solution advantageously may contain further ingredients, for example a salt, in particular sodium chloride, or a suitable buffer, for example a phosphate buffer. The preferred treatment is again dipping/immersing the biomedical article into the aqueous solution. The time period for this additional neutralization step is again not critical; usually a time period of ≦1 minute, preferably ≦30 seconds more preferably ≦10 seconds is sufficient to accomplish a further improvement of the surface coating. It is also possible to combine the shrinkage step and this further neutralization step. For example, shrinkage and neutralization may be done in one step by dipping the biomedical article in an aqueous solution of a weak base having a pH of, for example, from 7.5 to 10, for example in an aqueous NaHCO3 or the like solution.
  • The biomedical article then may be worked up and finished in a usual manner. For example, contact lenses are in general subjected to a sterilization step, which comprises, for example, autoclaving the contact lenses for a certain time period at an elevated temperature. For example, autoclaving for a time period of 20 minutes to 1.5 hours, in particular from 30 minutes to 1 hour, at a temperature of about 115 to 130° C., has proven as valuable.
  • According to the process of the invention, biomedical articles, in particular ophthalmic articles, are obtained that have a variety of unexpected advantages over those of the prior art, which make those articles very suitable for practical purposes, e.g. as contact lens for extended wear. For example, they do have a high surface wettability and lubricity. This can be demonstrated, for example, by the finger tip test showing a very slippery article surface; or by visual inspection; or by suitable contact angle measurements. For example, sessile drop static contact angles of coated and non-coated lenses are determined with a DSA 10 drop shape analysis system from Krüss (Krüss GmbH, Hamburg, Germany). While uncoated silicon hydrogel contact lenses in general have a water contact angle of 90 to 100° or above, a treatment according to the process of the invention significantly reduces said value. Further tools for assessing the superior quality of the surface coatings obtainable according to the process of the invention are ATR-FTIR measurements or the Sudan Black dye absorption test as described below in the Examples section.
  • In addition, biomedical devices, e.g. ophthalmic devices such as contact lenses, comprising a composite material of the invention have a very pronounced biocompatibility combined with good mechanical properties. Generally, there is low microbial adhesion and low bio-erosion while good mechanical properties can be for example found in a low friction coefficient and low abrasion properties. Moreover, the dimensional stability of the composite materials of the invention is excellent. In addition, the attachment of a hydrophilic surface coating at a given bulk material according to the invention does not affect its visual transparency.
  • According to the process of the invention biomedical articles such as contact lenses may be coated very fast, that is within seconds; nevertheless the coated articles are mechanically very stable and robust. No pre-treatment step or the like is necessary, the lenses may be coated directly following their manufacture. This makes the process of the invention highly adaptable into a high volume mass production process, such as the contact lens manufacturing process as disclosed in EP-A-969956 or EP-A-1047542.
  • It is particularly surprising that the surface treatment according to the present invention in general does not affect the properties of the underlying organic bulk material. While prior art coating processes often affect article properties such as transparency, ion permeability, oxygen transmissibility, water contents or device geometry (e.g. diameter of a contact lens), said parameters are not or at least not significantly affected by the process of the invention.
  • In the examples, if not indicated otherwise, amounts are amounts by weight; temperatures are given in degrees Celsius. Average water contact angles of coated and non-coated lenses are determined as described above.
    • EXAMPLES Example 1 Preparation of a Treatment Solution
  • 0.36 g of solid polyacrylic acid (Mn=90.000, Polyscience) is dissolved in a mixture of 80 ml ethanol (Merck # 1.00983.2511) and 0.98 ml of a 1.5 M hydrochloric acid in ethanol (Fluka # 19934) and diluted by additional EtOH to 100 ml total volume.
  • A droplet of the treatment solution indicates pH =2.0 with wet pH indicator paper (Merck # 1.09540.000).
    • Example 2 Preparation of a Soft Silicon Hydrogel Contact Lens Having Attached to its Surface a Polyacrylic Acid Coating (i) Preparation of the Silicon Hydrogel Contact Lens (ia) Preparation of PDMS Crosslinker I
  • In a 4-L beaker, 24.13 g of Na2CO3, 80 g of NaCl and 1.52 kg of deionized water are mixed to dissolve. In a separate 4-L beaker, 700 g of bis-3-aminopropyl-polydimethylsiloxane (Shin-Etsu, MW ca. 11500) are dissolved in 1000 g of hexane. A 4-L reactor is equipped with overhead stirring with turbine agitator and a 250-mL addition funnel with micro-flow controller. The two solutions are then charged to the reactor, and mixed for 15 minutes with heavy agitation to produce an emulsion. 14.5 g of acryloyl chloride are dissolved in 100 mL of hexane and charged to the addition funnel. The acryloyl chloride solution is added dropwise to the emulsion under heavy agitation over one hour. The emulsion is stirred for 30 minutes on completion of the addition and then agitation is stopped and the phases are allowed to separate overnight. The aqueous phase is decanted and the organic phase is washed twice with a mixture of 2.0 kg of 2.5% NaCl dissolved in water. The organic phase is then dried over magnesium sulfate, filtered to 1.0 μm exclusion, and concentrated on a rotary evaporator. The resulting oil is further purified by high-vacuum drying to constant weight. Analysis of the resulting product by titration reveals 0.175 mEq/g of C=C double bonds.
    • (ib) Preparation of PDMS Crosslinker II
  • In a 4-L beaker, 61.73 g of Na2CO3, 80 g of NaCl and 1.52 kg of deionized water are mixed to dissolve. In a separate 4-L beaker, 700 g of bis-3-aminopropyl-polydimethylsiloaxane (Shin-Etsu, MW ca. 4500) are dissolved in 1000 g of hexane. A 4-L reactor is equipped with overhead stirring with turbine agitator and a 250-mL addition funnel with micro-flow controller. The two solutions are then charged to the reactor, and mixed for 15 minutes with heavy agitation to produce an emulsion. 36.6 g of acryloyl chloride is dissolved in 100 mL of hexane and charged to the addition funnel. The acryloyl chloride solution is added dropwise to the emulsion under heavy agitation over one hour. The emulsion is stirred for 30 minutes on completion of the addition and then agitation is stopped and the phases are allowed to separate overnight. The aqueous phase is decanted and the organic phase is washed twice with a mixture of 2.0 kg of 2.5% NaCl dissolved in water. The organic phase is then dried over magnesium sulfate, filtered to 1.0 μm exclusion, and concentrated on a rotary evaporator. The resulting oil is further purified by high-vacuum drying to constant weight. Analysis of the resulting product by titration reveals 0.435 mEq/g of C=C double bonds.
    • (ic) Preparation of the Crosslinkable Copolymer
  • A 2-L jacketed reactor is equipped with a heating/chilling loop, reflux condenser, N2-inlet/vacuum adapter, feeding tube adapter and overhead mechanical stirring. A solution is generated by dissolving 90.00 g of PDMS crosslinker I according to (ia) and 30.00 g of PDMS crosslinker II according to (ib) in 480 g of 1-propanol. This solution is charged to the reactor and cooled to 8° C. The solution is degassed by evacuating to less than 15 mBar, holding at vacuum for 15 minutes, and then re-pressurizing with dry nitrogen. This degas procedure is repeated for a total of 3 times. The reactor is held under a blanket of dry nitrogen.
  • In a separate flask, a monomer solution is prepared by mixing 1.50 g of cysteamine hydrochloride, 0.3 g of AIBN, 55.275 g of DMA, 18.43 g of HEA and 364.5 g of 1-propanol. This solution is filtered with a Waterman 540 filter paper, and then added to the reactor through a degas unit and HPLC pump with a flow rate of 3.0 mL /minute. The reaction temperature is then elevated to 68° C. with a heating ramp about one hour.
  • In a second flask, a feeding solution is prepared by mixing 4.5 g of cysteamine hydrochloride and 395.5 g of 1-propanol and then filtering with Waterman 540 filter paper. When the reactor temperature reaches 68° C., this solution is slowly dosed into the reactor through the degasser/HPLC pump over 3 hours. The reaction is then continued at 68° C. for an additional 3 hours, on which heating has discontinued and the reactor is allowed to cool to room temperature.
  • The reaction mixture is transferred to a flask and stripped solvent at 40° C. under vacuum on a rotary evaporator until 1000 g of sample remained. The solution is then slowly mixed with 2000 g of deionized water with rapid agitation. Additional solvent is further removed until about 2000 g of sample remain. During this stripping process, the solution gradually becomes an emulsion. The resulting material is purified by ultrafiltration over a 10 kD molecular weight cut-off membrane until the permeate conductance is below 2.5 μS/cm.
  • This emulsion is then charged to a 2-L reactor equipped with overhead stirring, refrigeration loop, thermometer, and the pH meter and dispensing tip of a Metrohm Model 718 STAT Titrino. The reaction mixture is then cooled to 1° C. 7.99 g of NaHCO3 are charged to the emulsion and stirred to dissolve. The Titrino is set to maintain pH at 9.5 by intermittent addition of 15% sodium hydroxide solution. 11.59 mL of acryloyl chloride are then added over one hour using a syringe pump. The emulsion is stirred for another hour, then the Titrino is set to neutralize the reaction mixture by addition of a 15% solution of hydrochloric acid. The product is purified by ultrafiltration again with 10 kD molecular weight cut-off membrane until the permeate conductance is below 2.5 μS/cm. The final macromonomer is isolated by lypophilization.
    • (id) Preparation of Contact Lenses
  • 18.83 g of the polymer obtained according to step (ic) are dissolved in approximately 200 mL of 1-propanol, concentrated to ca. 70 g total solution weight, and filtered to 0.45 μm exclusion. 67.94 g of solution at 26.53% solids are recovered. 4.503 g of a 1% solution of 2-hydroxy-4′-hydroxyethyl-2-methylpropiophenone (IRGACURE®-2959, Ciba Specialty Chemicals) are added, and the solution is then concentrated to a final formulation having 60% solids.
  • 200 mg of the formulation are dosed into poly(propylene) contact lens molds and the molds are closed. The molds are then irradiated for 15 s with an ultraviolet light source having an intensity of 2.18 mW/cm2. The molds are then opened, and the contact lenses are removed from the mold halves.
    • (ie) Preparation of the Surface Coating
  • A hydrophobic silicon hydrogel contact lens obtained according to (id) above is placed on a lens holder. The lens holder with the lens is then immersed at room temperature for 5 sec into the treatment solution obtained according to Example 1. Following its removal from the treatment solution, the lens holder with the lens is rinsed for 2 sec in a water bath and subsequently treated for 2 sec in a phosphate buffered saline (pH 7.2). The contact lens is then transferred into a glass vial and sterilized for 30 min at 121° C. by autoclaving. The presence of the polyacrylic acid coating is proven by ATR-FTIR spectroscopy (absorption at 1720 cm−1 at pH 2 and at 1560-1620 cm−1 at pH 7.2). The hydrophilic surface coating is further investigated by visual wettability and hydrophilicity testing as well as contact angle measurements and the Sudan Black staining test (see Table I below).
    • Example 3 Preparation of a Soft Silicon Hydrogel Contact Lens having Attached to its Surface a Polyacrylic Acid Coating
  • Hydrophobic silicon hydrogel contact lenses (lotrafilcon A, copolymerization product of a mixed polysiloxane/perfluoroalkyl polyether crosslinker, TRIS and DMA) are subjected to the surface treatment as described in Example 2 (ie). The results are summarized in Table I below.
    • Example 4 Preparation of a Soft Silicon Hydrogel Contact Lens having Attached to its Surface a Polyacrylic Acid Coating
  • Hydrophobic silicon hydrogel contact lenses (lotrafilcon B, copolymerization product of a mixed polysiloxane/ perfluoroalkyl polyether crosslinker, TRIS and DMA) are subjected to the surface treatment as described in Example 2 (ie). The results are summarized in Table I below.
    • Example 5 Preparation of a Soft Silicon Hydrogel Contact Lens having Attached to its Surface a Polyacrylic Acid Coating
  • Hydrophobic silicon hydrogel contact lenses (galyfilcon, commercially available under the brand name Acuvue Advance®) are first of all extracted with 2-propanol (2 ml/lens), then rinsed with water several times and stored in a vessel in cold water.
  • For coating purposes a contact lens is taken directly out of the vessel and is subjected to the surface treatment as described in Example 2 (ie). The results are summarized in Table I below.
    • Example 6: Surface Characterization (i) Wettability
  • Qualitative assessment by visual inspection of the contact lens. The ranking is based on the observation, how fast a film of the storage solution on the surface of the autoclaved contact lens vanishes following the removal of the lens from the storage vial with tweezers.
  • 0=no wetting, i.e. no film on the surface, droplets at most
    1=slight or partial wetting; a film is present but tears more or less immediately (<5 sec)
    2=good wetting; a film on the surface is present and is rather stable ( film tearing >5 s)
    • (ii) Lubricity
  • Qualitative evaluation by contacting the lens surface with the finger tips.
    0=tacky or frictional surface
    1=indifferent surface with respect to tackiness/lubricity
    2=slippery surface
    (iii) water contact angle
  • The measurement is performed by the sessile drop method with a DSA 10 drop shape analysis system from Krüss GmbH, Germany with pure water (Fluka, surface tension 72.5 mN/M at 20° C.). For measurement purposes a contact lens is taken off the storage solution with tweezers and excess storage solution is removed by gentle shaking. The contact lens is placed on the male part of a contact lens mold and gently blotted with a dry and clean cloth. A water droplet (about 1 μl) is then dosed on the lens apex, and the change of the contact angle over time of this water droplet (WCA(t), circle fitting mode) is monitored; WCA is calculated by extrapolation of the graph WCA(t) to t=0.
    • (iv) ATR-FTIR
  • ATR-FTIR measurements are performed with a Nicolet FTIR spectrometer equipped with a ZnSe crystal in an overhead sample holder (45° angle of incidence) with micrometer controlled clamp-down facility. For measurement purposes, a dried contact lens (vacuum drying oven, 1 mbar, 25° C., 30 min) is placed on the crystal, fixed by the clamp and measured (about 256 scans). The ATR-Infrared absorbance spectra are all normalized to the signal at 2961 cm−1; assessment by comparison of the signal increase at 1720 cm−1 (vCOOH) with the signal at about 1631 cm−1 ( indicative for silicon hydrogel presence).
  • n=no change
    w=weak signal increase (<0.5)
    m=moderate signal increase (0.5-1.0)
    s=strong signal increase (>1)
    • (v) Sudan Black Dye Absorption Test
  • A 0.5% (w/w) Sudan Black dye solution is prepared by dissolving 0.5 g of Sudan Black B (Aldrich) over night in 100 g of vitamin E oil under stirring. For measurement purposes, the surface-treated lens is first of all autoclaved (30 min, 121° C.) in 2 ml of an phosphate buffered saline (pH 7.2) in a glass vial. The contact lens is then removed from the solution with tweezers and gently shaken so that most of the surface water is removed. The lens is then placed in the above prepared Sudan Black dye solution for 5 min. Thereafter the lens is removed from the dye-bath, and the excess dye solution is rinsed off with warm water. The lens is air-dried and assessed according to its degree of staining.
  • 2=no or almost no staining
    1=slight staining
    0=considerable staining
  • The values obtained with contact lenses as coated in Examples 2-5 and with the corresponding uncoated contact lenses (control) are summarized in Table I.
  • TABLE I
    Sudan
    Treatment Wetta- Lubric- WCA Black
    Example time [sec] bility ity [°] (wet) ATR-FTIR
    2 5 2 2 16 2 m
    2(Control) — 0 0 109 0 n
    3 5 2 2 23 2 s
    3(Control) — 0 0 105 0 n
    4 5 2 2 18 2 m
    4(Control) — 0 0 104 0 n
    5 5 2 2 25 2 Not
    measured
    5(Control) — 1 0 102 0 Not
    measured
    • Example 7 Preparation of a Polyacrylic Acid Coating on a Soft Silicone Hydrogel Contact Lens. Impact of Water Content and Treatment Time on the Hydrophilization of Lotrafilcon B Lenses (i) Preparation of Treatment Solutions
  • (ia) An ethanolic lens treatment solution (“solution I”) is prepared by dissolving 3.6 g of solid polyacrylic acid (Mn=90.000, Polyscience) in a mixture of 800 ml ethanol (Merck # 1.00983.2511) and 9.8 ml of a 1.5 M hydrochloric acid in ethanol (Fluka # 19934) and diluted by additional EtOH to 1000 ml total volume.
  • (ib) An aqueous lens treatment solution (“solution II”) is prepared by dissolving 3.6 g of solid polyacrylic acid (Mn=90.000 ) in a solution of 700 ml water and 3.6 ml of a 1 N aqueous hydrochloric acid solution and diluted with additional water to 1000 ml total volume.
  • A droplet of each treatment solutions indicates pH=2.0 with wet pH indicator paper (Merck # 1.09540.000).
  • By mixing of appropriate volume portions of solution II (V II) with those of solution I (V I) lens treatment solutions with different water contents are prepared according to the following equation:

  • c H20 =[V II/(V I +V II)]*100[%]
  • (ii) Lens Coating Process: The lens coating processes are performed with Lotrafilcon B lenses as described in Example 2 (ie) by variation of the treatment time (5 s, 10s, 30 s, 60 s and 300 s) and water content of the treatment solution cH20 (0%, 5%, 20%, 50% and 100%).
    (iii) Lens Surface Characterizations:
  • Lenses were evaluated and characterized by water contact angle, slipperiness, and Sudan Black staining test according to the methods described in Example 6.
  • The results are summarized in Tables 2 to 4 below.
  • TABLE 2
    Impact of treatment time and water content of the treatment
    solution on water contact angle of Lotrafilcon B lenses
    Treatment Time [s]
    cH2O [%] 5 10 30 60 300
    0 19 21 20 25 14
    5 17 37 31 24 21
    20 46 43 42 36 36
    50 66 71 49 52 57
    100 84 90 83 90 79
  • TABLE 3
    Impact of treatment time and water content of the treatment
    solution on lubricity of Lotrafilcon B lenses
    Treatment Time [s]
    cH2O [%] 5 10 30 60 300
    0 2 2 2 2 2
    5 2 2 2 2 2
    20 1 2 2 2 2
    50 1 1 1 2 2
    100 1 1 1 1 1
  • TABLE 4
    Impact of treatment time and water content of the treatment solution
    on the Sudan Black dye absorption test of Lotrafilcon B lenses
    Treatment Time [s]
    cH2O [%] 5 10 30 60 300
    0 2 2 2 2 2
    5 2 1 2 2 2
    20 1 1 1 2 2
    50 0 0 1 1 1
    100 0 0 0 0 0

Claims (13)

1. A process for the hydrophilic coating of a biomedical article, comprising: treating the biomedical article for a time period of ≦5 minutes with a solution of an organic solvent comprising a polyanionic compound with a number average molecular weight Mn of >5000, wherein the solution comprises less than 20% by weight of water, and wherein the solution is devoid of a cationic polymer.
2. A process according to claim 1, wherein the solution comprises less than 10% by weight of water.
3. A process according to claim 1, wherein the biomedical article is a soft contact lens comprising a hydrophobic bulk material selected from the group consisting of a silicon hydrogel, a perfluoroalkyl polyether and a mixture thereof.
4. A process according to claim 1, wherein the polyanionic compound is a polyacrylic acid or a copolymer of acrylic acid and a comonomer selected from the group consisting of methacrylic acid, itaconic acid, maleic acid, maleic anhydride, N-vinylpyrrolidone, methylvinylether, acrylamide, N,N-dimethylacrylamide and a monovinyl polyethylene oxide, in particular a polyacrylic acid.
5. A process according to claim 1, wherein the number average molecular weight Mn of the polyanionic compound is from 7500 to 1 million, preferably from 20000 to 750000, and in particular from 80000 to 500000.
6. A process according to claim 1, wherein the organic solvent is a C2-C4-alcohol or a glycol ether, in particular ethanol or diethylene glycol monoethylether.
7. A process according to claim 1, wherein the solution for treatment of the biomedical article is a solution of a polyacrylic acid or a copolymer of acrylic acid and a comonomer selected from the group consisting of methacrylic acid, maleic acid, maleic anhydride, itaconic acid, N-vinylpyrrolidone, methylvinylether, acrylamide, N,N-dimethylacrylamide and a monovinyl polyethylene oxide, in a C2-C4-alcohol or a diethyleneglycol mono-C1-C4-alkylether, wherein the number average molecular weight Mn of the polyacrylic acid homo- or copolymer is from 7500 to 1 million, and wherein the pH value of the solution is ≦4.
8. A process according to claim 1, wherein the solution for treatment of the biomedical article is a solution of a polyacrylic acid having a number average molecular weight Mn of from 20000 to 500000 in ethanol, wherein the pH value of the solution is from 1.5 to 3.5 and in particular from 1.8 to 3.
9. A process according to claim 1, wherein the time period of the treatment is ≦1 minute, preferably ≦30 seconds and in particular ≦10 seconds.
10. A process according to claim 1, further comprising a step of contacting the biomedical article with a solvent after the biomedical article is removed from the treatment solution, wherein the solvent has the ability to shrink the organic bulk material underlying the biomedical article, and wherein the solvent is miscible with the solvent of the treatment solution.
11. A process according to claim 10, further comprising a step of treating the biomedical article, after the shrinking step, with an aqueous solution comprising a neutral or slightly basic pH.
12. The coated biomedical article made according to claim 1.
13. The coated biomedical article made according to claim 1 is a coated contact lens.
US12/004,002 2006-12-21 2007-12-19 Process for the coating of biomedical articles Active 2030-12-29 US8158192B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06126835.5 2006-12-21
EP06126835 2006-12-21
EP06126835 2006-12-21

Publications (2)

Publication Number Publication Date
US20080152800A1 true US20080152800A1 (en) 2008-06-26
US8158192B2 US8158192B2 (en) 2012-04-17

Family

ID=38050928

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/004,002 Active 2030-12-29 US8158192B2 (en) 2006-12-21 2007-12-19 Process for the coating of biomedical articles

Country Status (8)

Country Link
US (1) US8158192B2 (en)
EP (1) EP2101838B1 (en)
JP (1) JP5473605B2 (en)
CN (1) CN101568354B (en)
AT (1) ATE489975T1 (en)
DE (1) DE602007010979D1 (en)
MY (1) MY148313A (en)
WO (1) WO2008074838A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090160074A1 (en) * 2007-12-20 2009-06-25 John Dallas Pruitt Method for making contact lenses
WO2012016098A1 (en) 2010-07-30 2012-02-02 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
WO2013074535A1 (en) 2011-11-15 2013-05-23 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
US8557334B2 (en) 2009-12-08 2013-10-15 Novartis Ag Silicone hydrogel lens with a covalently attached coating
US9005700B2 (en) 2011-10-12 2015-04-14 Novartis Ag Method for making UV-absorbing ophthalmic lenses
WO2016032926A1 (en) 2014-08-26 2016-03-03 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US9310627B2 (en) 2013-11-15 2016-04-12 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US9422447B2 (en) 2012-06-14 2016-08-23 Novartis Ag Azetidinium-containing copolymers and uses thereof
WO2017037610A1 (en) 2015-09-04 2017-03-09 Novartis Ag Method for producing contact lenses with durable lubricious coatings thereon
WO2017093834A1 (en) 2015-12-03 2017-06-08 Novartis Ag Contact lens packaging solutions
WO2017103793A1 (en) 2015-12-15 2017-06-22 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US9708087B2 (en) 2013-12-17 2017-07-18 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US9720138B2 (en) 2014-08-26 2017-08-01 Novartis Ag Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof
US9802339B2 (en) 2013-12-13 2017-10-31 Novartis Ag Method for making contact lenses
WO2018055491A1 (en) 2016-09-20 2018-03-29 Novartis Ag Process for producing contact lenses with durable lubricious coatings thereon
US9950483B2 (en) 2013-05-29 2018-04-24 Novartis Ag Method for determining the surface concentration of carboxyl groups on a lens
WO2018078598A1 (en) 2016-10-31 2018-05-03 Chnovartis Ag Method for producing surface coated contact lenses with wearing comfort
US10338408B2 (en) 2012-12-17 2019-07-02 Novartis Ag Method for making improved UV-absorbing ophthalmic lenses
US10517999B2 (en) * 2016-04-12 2019-12-31 Cardiac Pacemakers, Inc. Hydrophilic coatings through in situ surface polymerization
US10525170B2 (en) 2014-12-09 2020-01-07 Tangible Science, Llc Medical device coating with a biocompatible layer
US10830923B2 (en) 2017-12-13 2020-11-10 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010320647B2 (en) * 2009-11-20 2014-11-06 Sun Chemical B.V. Gas barrier coatings
EP2613180B1 (en) * 2012-02-01 2014-03-26 LensWista AG Silicon contact lens
CA2978635A1 (en) 2015-03-11 2016-09-15 University Of Florida Research Foundation, Inc. Mesh size control of lubrication in gemini hydrogels
EP3390026A1 (en) 2015-12-15 2018-10-24 Novartis AG Method for producing contact lenses with a lubricious surface
CA3061585C (en) 2017-06-07 2021-11-16 Alcon Inc. Silicone hydrogel contact lenses
AU2018282054B2 (en) 2017-06-07 2021-01-14 Alcon Inc. Silicone hydrogel contact lenses
EP3447475B1 (en) 2017-08-24 2020-06-17 Alcon Inc. Method and apparatus for determining a coefficient of friction at a test site on a surface of a contact lens
JP7564197B2 (en) 2019-11-04 2024-10-08 アルコン インク． Contact lenses having surfaces with different flexibility
EP4369081A3 (en) 2019-12-16 2024-05-29 Alcon Inc. Method for producing an ophthalmic product
HUE069050T2 (en) 2020-07-28 2025-02-28 Alcon Inc Contact lenses with softer lens surfaces
CN119731560A (en) 2022-08-17 2025-03-28 爱尔康公司 Contact lens having hydrogel coating thereon
CN119101422B (en) * 2023-12-27 2025-03-28 苏州银炙新材料科技有限公司 Antifouling developing coating material and preparation method and application thereof

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168112A (en) * 1978-01-05 1979-09-18 Polymer Technology Corporation Contact lens with a hydrophilic, polyelectrolyte complex coating and method for forming same
US4941997A (en) * 1987-07-13 1990-07-17 Ciba-Geigy Corporation Amphiphilic azo dyes and molecular aggregates thereof
US4973429A (en) * 1988-02-17 1990-11-27 Ciba-Geigy Corporation Organic materials with non-linear optical properties
US5208111A (en) * 1990-08-25 1993-05-04 Bayer Aktiengesellschaft One- or multi-layered layer elements applied to supports and their production
US5336797A (en) * 1992-12-30 1994-08-09 Bausch & Lomb Incorporated Siloxane macromonomers
US5509899A (en) * 1994-09-22 1996-04-23 Boston Scientific Corp. Medical device with lubricious coating
US5518767A (en) * 1993-07-01 1996-05-21 Massachusetts Institute Of Technology Molecular self-assembly of electrically conductive polymers
US5529727A (en) * 1994-07-20 1996-06-25 Bausch & Lomb Incorporated Method of treating contact lenses
US5700559A (en) * 1994-12-16 1997-12-23 Advanced Surface Technology Durable hydrophilic surface coatings
US5800412A (en) * 1996-10-10 1998-09-01 Sts Biopolymers, Inc. Hydrophilic coatings with hydrating agents
US6011082A (en) * 1997-06-02 2000-01-04 Pharmacia & Upjohn Ab Process for the modification of elastomers with surface interpreting polymer networks and elastomers formed therefrom
US6286955B1 (en) * 1999-12-15 2001-09-11 Tetsuya Sakai Biocompatible lens, and method of producing the same
US20010045676A1 (en) * 2000-02-04 2001-11-29 Winterton Lynn Cook Method for modifying a surface
US20010048975A1 (en) * 2000-02-04 2001-12-06 Winterton Lynn Cook Single-dip process for achieving a layer-by-layer-like coating
US20020006493A1 (en) * 2000-05-30 2002-01-17 Peter Chabrecek Coated articles
US20020039742A1 (en) * 2000-08-09 2002-04-04 Yoshihide Iwaki Fixation of nucleotide derivatives to solid carrier
US20020086160A1 (en) * 2000-08-24 2002-07-04 Yongxing Qiu Process for surface modifying substrates and modified substrates resulting therefrom
US6428839B1 (en) * 2000-06-02 2002-08-06 Bausch & Lomb Incorporated Surface treatment of medical device
US6451871B1 (en) * 1998-11-25 2002-09-17 Novartis Ag Methods of modifying surface characteristics
US6478423B1 (en) * 1999-10-12 2002-11-12 Johnson & Johnson Vison Care, Inc. Contact lens coating selection and manufacturing process
US20020182316A1 (en) * 2001-05-30 2002-12-05 Allen Gilliard Method and apparatus for applying a coating to an ophthalmic lens
US20030008154A1 (en) * 2001-05-30 2003-01-09 Celeste Aguado Polymeric materials for making contact lenses
US20030012872A1 (en) * 2001-05-30 2003-01-16 Yongxing Qiu Method for applying a coating to a medical device
US6531432B2 (en) * 2000-12-07 2003-03-11 Johnson & Johnson Vision Care, Inc. Contact lens packaging solutions
US20030052424A1 (en) * 2001-08-02 2003-03-20 Turner David C. Method for coating articles by mold transfer
US20030117579A1 (en) * 2001-11-14 2003-06-26 Morris Carol Ann Medical devices having antimicrobial coatings thereon
US20030125498A1 (en) * 2001-09-10 2003-07-03 Mccabe Kevin P. Biomedical devices containing internal wetting agents
US20030134132A1 (en) * 2002-01-09 2003-07-17 Winterton Lynn Cook Polymeric articles having a lubricious coating and method for making the same
US20030143335A1 (en) * 2000-08-24 2003-07-31 Yongxing Qiu Process for surface modifying substrates and modified substrates resulting therefrom
US20030162862A1 (en) * 2001-09-10 2003-08-28 Mccabe Kevin P. Biomedical devices containing internal wetting agents
US6632905B2 (en) * 1999-09-02 2003-10-14 Alcon Universal Ltd. Covalently-bound, hydrophilic coating compositions for surgical implants
US6699435B2 (en) * 1997-06-06 2004-03-02 Bausch & Lomb Incorporated Contact lens packing solutions
US20040047979A1 (en) * 2002-09-11 2004-03-11 Yongxing Qiu Method for applying an LbL coating onto a medical device
US20040067365A1 (en) * 2002-09-11 2004-04-08 Yongxing Qiu LbL-coated medical device and method for making the same
US20040108607A1 (en) * 2000-02-04 2004-06-10 Winterton Lynn Cook Method for modifying a surface
US20060251694A1 (en) * 2002-12-20 2006-11-09 Nielsen Bo R Hydrophilic coating and a method for the preparation thereof
US20080213460A1 (en) * 2005-01-17 2008-09-04 Maike Benter Method of Coating a Polymer Surface with a Polymer Containing Coating and an Item Comprising a Polymer Coated Polymer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3170785D1 (en) 1980-01-10 1985-07-11 Coopervision Inc Cross-linked polymers for contact lenses
GB2102070A (en) 1981-07-14 1983-01-26 Anglo Netherland Engineering C Assisted gas flow device
US4570629A (en) 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
JPH01158412A (en) 1986-12-26 1989-06-21 Daicel Chem Ind Ltd Cleaning and preserving liquid for contact lens
JP2578127B2 (en) 1987-08-20 1997-02-05 ト−メ−産業株式会社 Solution for contact lenses
JP3166298B2 (en) 1991-10-04 2001-05-14 株式会社ダイヘン Arc length control method for GMA welding
AU7061594A (en) 1993-06-18 1995-01-17 Polymer Technology Corporation Contact lens solution containing peo and cationic cellulose
AU7642894A (en) * 1993-08-30 1995-03-22 Nepera, Inc. Low friction, hydrophilic, biocompatible compositions
GB9415926D0 (en) 1994-08-04 1994-09-28 Biocompatibles Ltd New materials
JPH07256844A (en) 1994-03-18 1995-10-09 Teijin Ltd Laminated film and manufacture thereof
JPH07266443A (en) 1994-03-30 1995-10-17 Hoya Corp Manufacture of soft contact lens
US5760100B1 (en) 1994-09-06 2000-11-14 Ciba Vision Corp Extended wear ophthalmic lens
WO1996037241A1 (en) 1995-05-25 1996-11-28 Minnesota Mining And Manufacturing Company Process for producing biocompatible surfaces
US5807944A (en) 1996-06-27 1998-09-15 Ciba Vision Corporation Amphiphilic, segmented copolymer of controlled morphology and ophthalmic devices including contact lenses made therefrom
WO1998042497A2 (en) 1997-03-25 1998-10-01 Novartis Ag Molding processes
WO1998058990A1 (en) * 1997-06-20 1998-12-30 Coloplast A/S A hydrophilic coating and a method for the preparation thereof
TW429327B (en) 1997-10-21 2001-04-11 Novartis Ag Single mould alignment
KR20010033969A (en) 1998-01-09 2001-04-25 한스 루돌프 하우스 Coating of polymers
US20010036556A1 (en) 1998-10-20 2001-11-01 James S. Jen Coatings for biomedical devices
ATE410707T1 (en) * 1999-09-02 2008-10-15 Alcon Inc COVALENTLY BONDED HYDROPHILIC COATING COMPOSITIONS FOR IMPLANTS
EP1238293B1 (en) * 1999-10-12 2013-11-27 Johnson & Johnson Vision Care, Inc. Contact lens coating selection and manufacturing process
ES2222373T3 (en) 2000-03-24 2005-02-01 Novartis Ag RETICULAR OR POLYMERIZABLE PREPOLIMEROS.
US6689480B2 (en) 2000-05-10 2004-02-10 Toray Industries, Inc. Surface-treated plastic article and method of surface treatment
JP4776863B2 (en) 2000-05-30 2011-09-21 ノバルティス アーゲー Covered product
US6827966B2 (en) 2001-05-30 2004-12-07 Novartis Ag Diffusion-controllable coatings on medical device
WO2003066714A1 (en) 2002-02-07 2003-08-14 Lions Eye Institute Limited Method for improving the surface quality of hydrogel articles
US8172395B2 (en) * 2002-12-03 2012-05-08 Novartis Ag Medical devices having antimicrobial coatings thereon

Patent Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4168112A (en) * 1978-01-05 1979-09-18 Polymer Technology Corporation Contact lens with a hydrophilic, polyelectrolyte complex coating and method for forming same
US4321261A (en) * 1978-01-05 1982-03-23 Polymer Technology Corporation Ionic ophthalmic solutions
US4941997A (en) * 1987-07-13 1990-07-17 Ciba-Geigy Corporation Amphiphilic azo dyes and molecular aggregates thereof
US5068318A (en) * 1987-07-13 1991-11-26 Ciba-Geigy Corporation Diamenodinitroazo dyes
US4973429A (en) * 1988-02-17 1990-11-27 Ciba-Geigy Corporation Organic materials with non-linear optical properties
US5208111A (en) * 1990-08-25 1993-05-04 Bayer Aktiengesellschaft One- or multi-layered layer elements applied to supports and their production
US5336797A (en) * 1992-12-30 1994-08-09 Bausch & Lomb Incorporated Siloxane macromonomers
US5518767A (en) * 1993-07-01 1996-05-21 Massachusetts Institute Of Technology Molecular self-assembly of electrically conductive polymers
US5536573A (en) * 1993-07-01 1996-07-16 Massachusetts Institute Of Technology Molecular self-assembly of electrically conductive polymers
US5529727A (en) * 1994-07-20 1996-06-25 Bausch & Lomb Incorporated Method of treating contact lenses
US5509899A (en) * 1994-09-22 1996-04-23 Boston Scientific Corp. Medical device with lubricious coating
US5700559A (en) * 1994-12-16 1997-12-23 Advanced Surface Technology Durable hydrophilic surface coatings
US5800412A (en) * 1996-10-10 1998-09-01 Sts Biopolymers, Inc. Hydrophilic coatings with hydrating agents
US6011082A (en) * 1997-06-02 2000-01-04 Pharmacia & Upjohn Ab Process for the modification of elastomers with surface interpreting polymer networks and elastomers formed therefrom
US6699435B2 (en) * 1997-06-06 2004-03-02 Bausch & Lomb Incorporated Contact lens packing solutions
US6451871B1 (en) * 1998-11-25 2002-09-17 Novartis Ag Methods of modifying surface characteristics
US6632905B2 (en) * 1999-09-02 2003-10-14 Alcon Universal Ltd. Covalently-bound, hydrophilic coating compositions for surgical implants
US6478423B1 (en) * 1999-10-12 2002-11-12 Johnson & Johnson Vison Care, Inc. Contact lens coating selection and manufacturing process
US6286955B1 (en) * 1999-12-15 2001-09-11 Tetsuya Sakai Biocompatible lens, and method of producing the same
US20010045676A1 (en) * 2000-02-04 2001-11-29 Winterton Lynn Cook Method for modifying a surface
US20010048975A1 (en) * 2000-02-04 2001-12-06 Winterton Lynn Cook Single-dip process for achieving a layer-by-layer-like coating
US6793973B2 (en) * 2000-02-04 2004-09-21 Novartis Ag Single-dip process for achieving a layer-by-layer-like coating
US20040108607A1 (en) * 2000-02-04 2004-06-10 Winterton Lynn Cook Method for modifying a surface
US20020006493A1 (en) * 2000-05-30 2002-01-17 Peter Chabrecek Coated articles
US6428839B1 (en) * 2000-06-02 2002-08-06 Bausch & Lomb Incorporated Surface treatment of medical device
US20020039742A1 (en) * 2000-08-09 2002-04-04 Yoshihide Iwaki Fixation of nucleotide derivatives to solid carrier
US20030143335A1 (en) * 2000-08-24 2003-07-31 Yongxing Qiu Process for surface modifying substrates and modified substrates resulting therefrom
US20020086160A1 (en) * 2000-08-24 2002-07-04 Yongxing Qiu Process for surface modifying substrates and modified substrates resulting therefrom
US20040018295A1 (en) * 2000-08-24 2004-01-29 Yongxing Qiu Process for surface modifying substrates and modified substrates resulting therefrom
US6531432B2 (en) * 2000-12-07 2003-03-11 Johnson & Johnson Vision Care, Inc. Contact lens packaging solutions
US20020182316A1 (en) * 2001-05-30 2002-12-05 Allen Gilliard Method and apparatus for applying a coating to an ophthalmic lens
US6815074B2 (en) * 2001-05-30 2004-11-09 Novartis Ag Polymeric materials for making contact lenses
US20030012872A1 (en) * 2001-05-30 2003-01-16 Yongxing Qiu Method for applying a coating to a medical device
US20030008154A1 (en) * 2001-05-30 2003-01-09 Celeste Aguado Polymeric materials for making contact lenses
US20030052424A1 (en) * 2001-08-02 2003-03-20 Turner David C. Method for coating articles by mold transfer
US20030125498A1 (en) * 2001-09-10 2003-07-03 Mccabe Kevin P. Biomedical devices containing internal wetting agents
US20030162862A1 (en) * 2001-09-10 2003-08-28 Mccabe Kevin P. Biomedical devices containing internal wetting agents
US20030117579A1 (en) * 2001-11-14 2003-06-26 Morris Carol Ann Medical devices having antimicrobial coatings thereon
US20030134132A1 (en) * 2002-01-09 2003-07-17 Winterton Lynn Cook Polymeric articles having a lubricious coating and method for making the same
US20040047979A1 (en) * 2002-09-11 2004-03-11 Yongxing Qiu Method for applying an LbL coating onto a medical device
US20040067365A1 (en) * 2002-09-11 2004-04-08 Yongxing Qiu LbL-coated medical device and method for making the same
US20060251694A1 (en) * 2002-12-20 2006-11-09 Nielsen Bo R Hydrophilic coating and a method for the preparation thereof
US20080213460A1 (en) * 2005-01-17 2008-09-04 Maike Benter Method of Coating a Polymer Surface with a Polymer Containing Coating and an Item Comprising a Polymer Coated Polymer

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009085902A1 (en) 2007-12-20 2009-07-09 Novartis Ag Method for making contact lenses
US7780879B2 (en) 2007-12-20 2010-08-24 Novartis Ag Method for making contact lenses
US8092724B2 (en) 2007-12-20 2012-01-10 Novartis Ag Method for making contact lenses
US20090160074A1 (en) * 2007-12-20 2009-06-25 John Dallas Pruitt Method for making contact lenses
US8440735B2 (en) 2007-12-20 2013-05-14 Novartis Ag Method for making contact lenses
US8557334B2 (en) 2009-12-08 2013-10-15 Novartis Ag Silicone hydrogel lens with a covalently attached coating
US9244200B2 (en) 2010-07-30 2016-01-26 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US9239409B2 (en) 2010-07-30 2016-01-19 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US8529057B2 (en) 2010-07-30 2013-09-10 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
EP2638879A2 (en) 2010-07-30 2013-09-18 Novartis AG Silicone hydrogel lenses with water-rich surfaces
US9507173B2 (en) 2010-07-30 2016-11-29 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
EP2705808A2 (en) 2010-07-30 2014-03-12 Novartis AG Silicone hydrogel lenses with water-rich surfaces
US8939577B2 (en) 2010-07-30 2015-01-27 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US8944592B2 (en) 2010-07-30 2015-02-03 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
US8480227B2 (en) 2010-07-30 2013-07-09 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US10781340B2 (en) 2010-07-30 2020-09-22 Alcon Inc. Silicone hydrogel lenses with water-rich surfaces
US9816009B2 (en) 2010-07-30 2017-11-14 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
EP4553545A2 (en) 2010-07-30 2025-05-14 Alcon Inc. Method for producing silicon hydrogel contact lenses with crosslinked hydrophilic coatings thereon
US9738813B2 (en) 2010-07-30 2017-08-22 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
WO2012016098A1 (en) 2010-07-30 2012-02-02 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
US9411171B2 (en) 2010-07-30 2016-08-09 Novartis Ag Silicone hydrogel lenses with water-rich surfaces
US9005700B2 (en) 2011-10-12 2015-04-14 Novartis Ag Method for making UV-absorbing ophthalmic lenses
US9505184B2 (en) 2011-11-15 2016-11-29 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
WO2013074535A1 (en) 2011-11-15 2013-05-23 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
US9422447B2 (en) 2012-06-14 2016-08-23 Novartis Ag Azetidinium-containing copolymers and uses thereof
US10100219B2 (en) 2012-06-14 2018-10-16 Novartis Ag Azetidinium-containing copolymers and uses thereof
US11181754B2 (en) 2012-08-27 2021-11-23 Tangible Science, Llc Contact lens with a hydrophilic layer
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US10451896B2 (en) 2012-08-27 2019-10-22 Tangible Science, Llc Contact lens with a hydrophilic layer
US10338408B2 (en) 2012-12-17 2019-07-02 Novartis Ag Method for making improved UV-absorbing ophthalmic lenses
US9950483B2 (en) 2013-05-29 2018-04-24 Novartis Ag Method for determining the surface concentration of carboxyl groups on a lens
US11433628B2 (en) 2013-11-15 2022-09-06 Tangible Science, Inc. Contact lens with a hydrophilic layer
US9310627B2 (en) 2013-11-15 2016-04-12 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US10330951B2 (en) 2013-11-15 2019-06-25 Tangible Science, Llc Contact lens with a hydrophilic layer
US9802339B2 (en) 2013-12-13 2017-10-31 Novartis Ag Method for making contact lenses
US9708087B2 (en) 2013-12-17 2017-07-18 Novartis Ag Silicone hydrogel lens with a crosslinked hydrophilic coating
WO2016032926A1 (en) 2014-08-26 2016-03-03 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US9720138B2 (en) 2014-08-26 2017-08-01 Novartis Ag Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof
US11002884B2 (en) 2014-08-26 2021-05-11 Alcon Inc. Method for applying stable coating on silicone hydrogel contact lenses
US10525170B2 (en) 2014-12-09 2020-01-07 Tangible Science, Llc Medical device coating with a biocompatible layer
US11260150B2 (en) 2014-12-09 2022-03-01 Tangible Science, Inc. Medical device coating with a biocompatible layer
WO2017037610A1 (en) 2015-09-04 2017-03-09 Novartis Ag Method for producing contact lenses with durable lubricious coatings thereon
US9810812B2 (en) 2015-09-04 2017-11-07 Novartis Ag Method for producing contact lenses with durable lubricious coatings thereon
WO2017093834A1 (en) 2015-12-03 2017-06-08 Novartis Ag Contact lens packaging solutions
EP3543004A1 (en) 2015-12-03 2019-09-25 Novartis AG Contact lens packaging solutions
US9829723B2 (en) 2015-12-03 2017-11-28 Novartis Ag Contact lens packaging solutions
WO2017103793A1 (en) 2015-12-15 2017-06-22 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US10449740B2 (en) 2015-12-15 2019-10-22 Novartis Ag Method for applying stable coating on silicone hydrogel contact lenses
US10517999B2 (en) * 2016-04-12 2019-12-31 Cardiac Pacemakers, Inc. Hydrophilic coatings through in situ surface polymerization
WO2018055491A1 (en) 2016-09-20 2018-03-29 Novartis Ag Process for producing contact lenses with durable lubricious coatings thereon
US11385478B2 (en) 2016-09-20 2022-07-12 Alcon Inc. Process for producing contact lenses with durable lubricious coatings thereon
US10718960B2 (en) 2016-10-31 2020-07-21 Alcon Inc. Method for producing contact lenses with wearing comfort
WO2018078598A1 (en) 2016-10-31 2018-05-03 Chnovartis Ag Method for producing surface coated contact lenses with wearing comfort
US10830923B2 (en) 2017-12-13 2020-11-10 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses
US11256003B2 (en) 2017-12-13 2022-02-22 Alcon Inc. Weekly and monthly disposable water gradient contact lenses
US11029446B2 (en) 2017-12-13 2021-06-08 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses
US11029447B2 (en) 2017-12-13 2021-06-08 Alcon Inc. Method for producing MPS-compatible water gradient contact lenses

Also Published As

Publication number Publication date
DE602007010979D1 (en) 2011-01-13
ATE489975T1 (en) 2010-12-15
MY148313A (en) 2013-03-29
JP5473605B2 (en) 2014-04-16
CN101568354B (en) 2013-05-22
JP2010513966A (en) 2010-04-30
WO2008074838A1 (en) 2008-06-26
EP2101838B1 (en) 2010-12-01
US8158192B2 (en) 2012-04-17
CN101568354A (en) 2009-10-28
EP2101838A1 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
US8158192B2 (en) Process for the coating of biomedical articles
EP2234798B1 (en) Method for coating silicone hydrogels
EP2496987B1 (en) A silicone hydrogel lens with a grafted hydrophilic coating
TWI616704B (en) A method for producing a polyoxyl hydrogel contact lens having a crosslinked hydrophilic coating, a polyoxyhydrogel contact lens product obtained therefrom, and an ophthalmic lens product comprising the same
JP4991075B2 (en) Surface treatment of silicone medical devices
US8460743B2 (en) Coating process for ophthalmic lenses
JP2004512866A (en) Method for applying a polymer lens coating
JP2003535626A (en) Surface treatment of medical devices
JP4980213B2 (en) Ophthalmic lens solution containing at least one silicone-containing component
KR20010033969A (en) Coating of polymers
CN111295601B (en) Method of making a coated contact lens
US7858337B2 (en) Process for the manufacture of a composite material

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOTHE, HARALD;MATSUZAWA, YASUO;SEIFERLING, BERNHARD;AND OTHERS;REEL/FRAME:020475/0888;SIGNING DATES FROM 20071210 TO 20071213

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOTHE, HARALD;MATSUZAWA, YASUO;SEIFERLING, BERNHARD;AND OTHERS;SIGNING DATES FROM 20071210 TO 20071213;REEL/FRAME:020475/0888

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: ALCON INC., SWITZERLAND

Free format text: CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019;ASSIGNOR:NOVARTIS AG;REEL/FRAME:051454/0788

Effective date: 20191111

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12

OSZAR »